Prognosis and treatment outcomes for patients with stage IA triple-negative breast cancer

Paolo Tarantino; Julieta Leone; Carlos T Vallejo; Rachel A Freedman; Adrienne G Waks; Olga Martínez-Sáez; Ana Garrido-Castro; Filipa Lynce; Nabihah Tayob; Nancy U Lin; Sara M Tolaney; Jose P Leone

doi:10.1038/s41523-024-00634-6

Prognosis and treatment outcomes for patients with stage IA triple-negative breast cancer

NPJ Breast Cancer. 2024 Apr 4;10(1):26. doi: 10.1038/s41523-024-00634-6.

Authors

Paolo Tarantino^{1

2

3

4}, Julieta Leone⁵, Carlos T Vallejo⁵, Rachel A Freedman^{1

2

3}, Adrienne G Waks^{1

2

3}, Olga Martínez-Sáez^{1

2

6

7}, Ana Garrido-Castro^{1

2

3}, Filipa Lynce^{1

2

3}, Nabihah Tayob^{1

3}, Nancy U Lin^{1

2

3}, Sara M Tolaney^{1

2

3}, Jose P Leone^{8

9

10}

Affiliations

¹ Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
² Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA, USA.
³ Harvard Medical School, Boston, MA, USA.
⁴ Department of Oncology and Onco-Hematology, University of Milan, Milan, Italy.
⁵ Grupo Oncológico Cooperativo del Sur, Neuquén, Argentina.
⁶ Medical Oncology Department, Hospital Clinic of Barcelona, Barcelona, Spain.
⁷ Translational Genomics and Targeted Therapeutics in Solid Tumors, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain.
⁸ Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. JoseP_Leone@dfci.harvard.edu.
⁹ Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA, USA. JoseP_Leone@dfci.harvard.edu.
¹⁰ Harvard Medical School, Boston, MA, USA. JoseP_Leone@dfci.harvard.edu.

Abstract

To evaluate the role of chemotherapy in stage IA triple-negative breast cancer, we conducted a retrospective population-based study including 8601 patients. The use of chemotherapy significantly increased from 2010 to 2019 in patients with T1b and T1c tumors (p = 0.001 and p < 0.001, respectively). Receipt of chemotherapy was associated with improved breast cancer-specific survival (BCSS, adjusted hazard ratio = 0.70; p = 0.006), particularly in patients with T1c tumors (5-year BCSS 94.5% vs. 91.2%).